Riyad N H Seervai

8PUBLICATIONS
44CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityMolecular targetsAllergyMedical biochemistry - proteins and peptides (incl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 02, 2026
When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung.

Avilasha Sinha, Riyad N H Seervai, Katie M Vlastelica

|May 07, 2023
Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells.

Mario L Marques-Piubelli, Riyad N H Seervai, Kumaran M Mudaliar

|Sep 07, 2022
The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.

Riyad N H Seervai, Sarah K Friske, Emily Y Chu

|Jul 18, 2022
Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies.

Riyad N H Seervai, Avilasha Sinha, Rajan P Kulkarni

|Dec 10, 2021
Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.

Riyad N H Seervai, Meghan Heberton, Woo Cheal Cho

|Oct 08, 2021
Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy.

Riyad N H Seervai, Woo Cheal Cho, Emily Y Chu

Pageof 2

Frequent Collaborators

4 joint publications

Jonathan L Curry

4 joint publications

Woo Cheal Cho

4 joint publications

Carlos A Torres-Cabala

3 joint publications

Phyu P Aung